Hoffmann-La Roche registers Phase III trial of enicepatide versus tirzepatide in type 2 diabetes
The study, led by Hoffmann-La Roche with Chugai Pharmaceutical as collaborator, plans to enroll 948 participants and begin on December 1, 2026. It will evaluate the efficacy and safety of enicepatide, a glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor (GLP-1/GIP) receptor agonist (RA), compared with tirzepatide in participants with type 2 diabetes mellitus (T2DM) and inadequate glycemic control on oral glucose-lowering medications.
Primary source
ClinicalTrials.gov registry record, October 22, 2026
A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participants With Type 2 Diabetes and Inadequate Blood Sugar Control on Oral Glucose-Lowering Medications
Machine-summarized from the source above; not independently reported. How we use automation